Free Trial
→ Most traders are panicking. We’re cashing in (From Crypto Swap Profits) (Ad)
NASDAQ:HURA

TuHURA Biosciences 9/18/2023 Earnings Report

TuHURA Biosciences logo
$3.73 -0.17 (-4.36%)
Closing price 05/6/2025 04:00 PM Eastern
Extended Trading
$3.98 +0.25 (+6.60%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Earnings HistoryForecast

TuHURA Biosciences EPS Results

Actual EPS
-$68.18
Consensus EPS
-$6.29
Beat/Miss
Missed by -$61.89
One Year Ago EPS
N/A

TuHURA Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

TuHURA Biosciences Announcement Details

Quarter
Date
9/18/2023
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

TuHURA Biosciences' next earnings date is estimated for Tuesday, May 13, 2025, based on past reporting schedules.

Conference Call Resources

TuHURA Biosciences Earnings Headlines

TuHURA Biosciences, Inc. (HURA)
May 6 at 3:30 PM | finance.yahoo.com
Innovative Immune Therapy Approach Drives Buy Rating for TuHURA Biosciences
May 6 at 2:43 PM | tipranks.com
Shocking AI play that’s beats Nvidia by a country mile
You’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is about to announce could change the AI market once again. Experts already predict the total addressable market could climb past $20 trillion. But Sykes believes most investors have missed what’s coming next. He’s tracking a new shift — and says the biggest gains are still ahead.
May 7, 2025 | Timothy Sykes (Ad)
TuHURA Biosciences, Inc. Initiates Phase 1b/2a Study of IFx-Hu2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in First Line Treatment for Metastatic Merkel Cell Carcinoma of Unknown Primary Origin (MCCUP)
May 5 at 8:00 AM | prnewswire.com
TuHURA And Kineta Present Updated Results From Phase I-II Study Of KVA12123
April 30, 2025 | nasdaq.com
TuHURA Biosciences: Promising Developments in Anti-VISTA Antibody and DNA-based Immune Activator Justify Buy Rating
April 29, 2025 | tipranks.com
See More TuHURA Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like TuHURA Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on TuHURA Biosciences and other key companies, straight to your email.

About TuHURA Biosciences

TuHURA Biosciences (NASDAQ:HURA), Inc. (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma. In addition to its innate immune response agonist candidates, TuHURA is leveraging its Delta receptor technology to develop first-in-class bi-specific ADCs, and PDCs targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.

View TuHURA Biosciences Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles